Natriuretic peptide testing in primary care patients

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 11, 2008, Pages 1533-1542

  Emdin, Michele ^a,c   Fontana, Marianna ^a   Poletti, Roberta ^a   Gabutti, Alessandra ^a   Mammini, Chiara ^a   Rossi, Andrea ^a   Pastormerlo, Luigi Emilio ^b   Masi, Lorenzo ^a   Passino, Claudio ^a,b   Clerico, Aldo ^b,c  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c CNR   (Italy)

Author keywords

B type natriuretic peptides; Diagnosis; Heart failure; Primary care; Prognosis; Screening

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ASSAY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEART DISEASE; HEART FAILURE; HUMAN; IMMUNORADIOMETRIC ASSAY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; SCREENING TEST;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 56549108947     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.297     Document Type: Conference Paper

References (106)

1. Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003;138:907-16.
2. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. J Am Med Assoc 2006;296:2209-16.
3. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006 20;113:2851-60.
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
5. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361:1843-8.
6. Hunt SA. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82.
7. Greenfield S, Nelson EC, Zubkoff M, Manning W, Rogers W, Kravitz RL, et al. Variations in resource utilization among medical subspecialties and systems of care. Results from the Medical Outcomes Study. J Am Med Assoc 1992;267:1624-30.
8. Cohen JJ. Transforming the size and composition of the physician work force to meet the demands of health care reform. N Engl J Med 1993;329:1810-2.
9. Harjai KJ, Boulos LM, Smart FW, Turgut T, Krousel-Wood MA, Stapleton DD, et al. Effects of caregiver specialty on cost and clinical outcomes following hospitalization for heart failure. Am J Cardiol 1998;82:82-5.
10. Ezekowitz JA, van Walraven C, McAlister FA, Armstrong PW, Kaul P. Impact of specialist follow-up in outpatients with congestive heart failure. Can Med Assoc J 2005;172:189-94.
11. Reis SE, Holubkov R, Edmundowicz D, McNamara DM, Zell KA, Detre KM, et al. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997;30:733-8.
12. Auerbach AD, Hamel MB, Davis RB, Connors AF Jr, Regueiro C, Desbiens N, et al. Resource use and survival of patients hospitalized with congestive heart failure: differences in care by specialty of the attending physician. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 2000;132:191-200.
13. NICE (National Institute of Clinical Excellence). Clinical Guideline 5. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care. London, July 2003:1-44.
14. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
15. Niemeinen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
16. Adams KF, Lindenfeld J, Arnold JM, Baker DW, Barnard DH, Baughman KL. Executive summary: HFSA 2006 comprehensive heart failure practice guidelines. J Cardiac Fail 2006;12:10-38.
17. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem 2004;50:33-50.
18. Emdin M, Passino C, Prontera C, Fontana M, Poletti R, Gabutti A, et al. Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure. Clin Chem 2007;53:1264-72.
19. Emdin M, Clerico A, Clemenza F, Galvani M, Latini R, Masson S, et al. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 2005;6:430-46.
20. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, et al. Quality specification for B-type natriuretic peptide assays. Clin Chem 2005;1:486-93.
21. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson, RH, Cannon CP, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure. Circulation 2007;116:e95-8.
22. De Lemos JA, Hildebrandt P. Amino-terminal pro-B-type natriuretic peptides: testing in general populations. Am J Cardiol 2008;101(Suppl 3):S16-20.
23. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-21.
24. Bossuyt PM. Study design and quality of evidence. In: Price CP, Christenson RH, editors. Evidence-based laboratory medicine. From principles to outcome. Washington, DC: AACC Press, 2003:75-92.
25. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure [review]. Arch Intern Med 2004;164:1978-84.
26. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 2005;51:2245-51.
27. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 2008;101(Suppl 3):S25-8.
28. Freitag MH, Vasan RS. Screening for left ventricular systolic dysfunction: the use of B-type natriuretic peptide. Heart Fail Monit 2003;4:38-44.
29. Silver MA, Pisano C. High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs. Congest Heart Fail 2003;9:127-32.
30. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. J Am Med Assoc 2002;288:1252-9.
31. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-5.
32. Ueda R, Yokouchi M, Suzuki T, Otomo E, Katagiri T. Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 2003;114:266-70.
33. Luchner A, Burnett JC, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-8.
34. McDonagh T, Robb S, Murdoch D, Morton J, Ford I. Biochemical detection of left ventricular systolic dysfunction. Lancet 1998;351:9-13.
35. Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. Br Med J 2000;320:906-8.
36. Aguilar J, Martinez A, Gil J. Valor del nivel de NT-proBNP en poblacion adulta extrahospitalaria. Rev Esp Cardiol 2003;56:236-44.
37. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90:297-303.
38. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004;109:3176-81.
39. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345-53.
40. Ng L, Loke I, Davies JE. Identification of previously undiagnosed LVSD: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 2003;5:775-82.
41. Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004;148:951-7.
42. Feola M, Aspromonte N, Canali C, Ceci V, Giovinazzo P, Dilani L, et al. Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure. Am J Cardiol 2005;96:705-9.
43. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003;26:2081-7.
44. Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of NT-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004;27:1929-35.
45. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, et al. CREED Investigators. The Cardiovascular Risk Extended Evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001;59:1559-66.
46. Nishikimi T, Futoo Y, Tamano K, Takahashi M, Suzuki T, Minami J, et al. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 2001;37:1201-8.
47. Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001;76:1111-9.
48. Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamide K, Yoshihara F, et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004;44:420-8.
49. Mark PB, Stewart GA, Gansevoort RT, Petrie CJ, McDonagh TA, Dargie HJ, et al. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant 2006;21:402-10.
50. deFilippi CR, Seliger SL, Maynard S, Christenson RH. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007;53:1511-9.
51. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.
52. Yasutake H, Seino Y, Kashiwagi M, Honma H, Matsuzaki T, Takano T. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 2005;102:259-68.
53. Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362-3.
54. Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000;104:158-63.
55. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4-9.
56. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005;51:1405-10.
57. Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007;53:813-22.
58. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008;38:101-13.
59. Landray M, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. Br Med J 2000;320:985-6.
60. Nielsen L, Svanegaard J, Klitgaard N. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004;6:63-70.
61. Gustafsson F, Badskjaer J, Stensgaard F. Value of N-terminal proBNP in the diagnosis of LVSD in primary care patients referred for echocardiography. Heart Drug 2003;3:141-6.
62. Koschack J, Scherer M, Lüers C, Kochen MM, Wetzel D, Kleta S, et al. Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care. BMC Fam Pract 2008;25:9-14.
63. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003;42:1793-800.
64. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, et al. The diagnostic accuracy of plasma BNP and NT-proBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537-41.
65. Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006;56:327-33.
66. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-7.
67. Clerico A, Prontera C, Emdin M, Passino C, Storti S, Poletti R, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma BNP and NT-proBNP concentrations. Clin Chem 2005;51:445-7.
68. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004;42:37-44.
69. Panteghini M, Clerico A. Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. Clin Lab 2004;50:325-31.
70. Vittorini S, Prontera C, Zucchelli GC, Clerico A. Cardiac natriuretic hormones: methodological aspects. Immuno-Analyse Biol Spec 2007;22:209-72.
71. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005;330:625-33.
72. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic peptide predicts mortality in the elderly. Heart 1997;77:264-7.
73. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799-807.
74. Kellett J. Prediction of in-hospital mortality by brain natriuretic peptide levels and other independent variables in acutely ill patients with suspected heart disease. Can J Cardiol 2004;20:686-90.
75. Isnard R, Pousset F, Chafirovskaia O, Carayon A, Hulot JS, Thomas D, et al. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J 2003;146:729-35.
76. de Groote P, Dagorn J, Soudan B, Lamblin N, McFadden E, Bauters C. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004;43:584-9.
77. Passino C, Severino S, Poletti R, Piepoli MF, Mammini C, Clerico A, et al. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol 2006;47:1835-9.
78. Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 2004;45:155-63.
79. Berger R, Huelsmann M, Strecker K, Moertl D, Moser P, Bojic A, et al. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur J Clin Invest 2005;35:24-31.
80. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9.
81. Van Beneden R, Gurne O, Selvais PL, Ahn SA, Robert AR, Ketelslegers JM, et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004;10:490-5.
82. Alehagen U, Dahlstrom U, Lindahl TL. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004;92:1250-8.
83. Ishii J, Cui W, Kitagawa F, Kuno T, Nakamura Y, Naruse H, et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 2003;49:2020-6.
84. Fonarow GC, Horwich TB. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure [review]. Rev Cardiovasc Med 2003; Suppl 4):S20-8.
85. Vasan S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62.
86. Marshall DA, O'Brien BJ. Economic evaluation of diagnostic tests. In: Price PC, Christensen RH, editors. Evidence-based laboratory medicine - from principles to outcomes. Washington, DC: AACC Press, 2003:159-86.
87. Logeart D, Saudubray C, Beyne P, Thabut G, Ennezat PV, Chavelas C, et al. Comparative values of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 2002;40:1794-800.
88. Ogawa K, Oida A, Sugimura H, Kaneko N, Nogi N, Hasumi M, et al. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: comparison of electrocardiography, chest radiography and echocardiography. Circ J 2002;66:122-6.
89. Dokainish H, Zoghbi WA, Lakkis NM, Quinones MA, Nagueh SF. Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. Am J Cardiol 2004;93:1130-5.
90. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-20.
91. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43:1019-26.
92. Arques S, Roux E, Sbragia P, Ambrosi P, Taieb L, Pieri B, et al. Accuracy of tissue Doppler echocardiography in the emergency diagnosis of decompensated heart failure with preserved left ventricular systolic function: comparison with B-type natriuretic peptide measurement. Echocardiography 2005;22:657-64.
93. Nakamura M, Tanaka F, Sato K, Segawa T, Nagano M. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. J Card Fail 2005;11:705-12.
94. Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 2005;128:21-9.
95. Aspromonte N, Ceci V, Chiera A, Coletta C, D'Eri A, Feola M, et al. Rapid brain natriuretic peptide test and Doppler echocardiography for early diagnosis of mild heart failure. Clin Chem 2006;52:1802-8.
96. Dokainish H, Zoghbi WA, Ambriz E, Lakkis NM, Quinones MA, Nagueh SF. Comparative cost-effectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure. Am J Cardiol 2006;97:400-3.
97. Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006;56:327-33.
98. Mueller C, Laule-Kilian K, Schindler C, Klima T, Frana B, Rodriguez D, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006;166:1081-7.
99. Nakamura M, Sakai T, Osawa M, Onoda T, Yonezawa S, Okayama A, et al. Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. Int Heart J 2005;46:477-87.
100. Alehagen U, Svensson E, Dahlström U. Natriuretic peptide biomarkers as information indicators in elderly patients with possible heart failure followed over six years: a head-to-head comparison of four cardiac natriuretic peptides. J Card Fail 2007;13:452-61.
101. Rutten FH, Cramer MJ, Zuithoff NP, Lammers JW, Verweij W, Grobbee DE, et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail 2007;9:651-9.
102. Vittorini S, Clerico A. Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. Clin Chem Lab Med 2008;6:748-63.
103. Swaanenburg JC, Visser-VanBrummen PJ, DeJongste MJ, Tiebosch AT. The content and distribution of troponin I, troponin T, myoglobin, and alpha-hydrobutyric acid dehydrogenase in the human heart. Am J Clin Pathol 2001;115:770-7.
104. Lukowicz TV, Fischer M, Hense HW, Döring A, Stritzke J, Riegger G, et al. BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur J Heart Fail 2005;7:525-31.
105. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. J Am Med Assoc 2003;289:194-202.
106. Ahmed A, Allman RM, Kiefe CI, Person SD, Shaneyfelt TM, Sims RV, et al. Association of consultation between generalists and cardiologists with quality and outcomes of heart failure care. Am Heart J 2003;5:1086-93.